Kaye Scholer represented Novartis subsidiary Sandoz, a world leader in generic pharmaceuticals, in a collaboration agreement with biotechnology company MedinCell. Under terms of the agreement, which was announced February 4, the alliance will develop and commercialize long-acting injectable drug products based on BEPO™ technology, with a primary focus on oncology.
The technology to deliver long-acting injectable drugs is rapidly advancing the world of pharmacology. The ability to provide a subcutaneous controlled release of drugs for days, weeks or even months has the potential to offer significant advantages over current delivery mechanisms, including patient compliance with a prescription regimen, efficacy and tolerability.
Corporate partner Aaron Gardner represented Sandoz in this transaction.
Also of Interest
- Bloomberg Business: Moriarty Returns for “Taking Stock” ETFs & Bitcoin Podcast September 22, 2016 • Media Mentions
- O’Keefe Featured in the Daily Journal on the 2016 Proxy Season September 15, 2016 • Media Mentions
- Pro Bono Team Advances CodeEd’s Comp Sci Efforts for Coeds September 14, 2016 • Client Successes
- SEC Proposes Exhibit Hyperlink Requirements September 8, 2016 • Client Alerts
- Arbisser Featured in The Recorder and Law360... September 7, 2016 • Media Mentions
- Consumer Products: Adapting to Innovation Fall 2016 • Reports / Newsletters
- ILS and Zinsser Analytic Shareholders Sell to Gardner Denver Medical September 2, 2016 • Client Successes
- Kaye Scholer Secures Dismissal of Merger-Related Class Action Against Baltic Trading September 1, 2016 • Client Successes
- Kaye Scholer Advises Veracen on Merger of Equals with Turner Investments August 31, 2016 • Client Successes